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ABSRACT
Objectives: The objective of this study is to assess the impact of medication
synchronization (med sync) on medication adherence for three drug classes under the CMS Star
Rating system i.e. oral diabetes, hypertension and cholesterol.
Methods: A quasi-experimental pre-post study design was employed using pharmacy
prescription fill data from various independent community pharmacies located in different
regions of Mississippi. Using Proportion of Days Covered (PDC), medication adherence before
and after the med sync was calculated. Total study period of one year for each patient including
six months of pre-period and post-period was used for the analysis. Descriptive statistics were
calculated. Wilcoxon-Signed Rank test was performed to compare the pre-period adherence to
post-period adherence. Proportion of adherent patients before and after the med sync were also
compared using McNemar’s Exact Test. Using the obtained 2x2 contingency table odds ratio of
being adherent in post-period as compared to pre-period was calculated.
Results: A total of 56, 89 and 77 patients were found to meet the inclusion/exclusion
criteria in diabetes, hypertension and cholesterol drug categories, respectively. The approximate
average age of the patients for the three drug classes was as follows: diabetes 66 years (23-87
years, ± 11.03), hypertension: 70 years (41-101 years, ± 11.53) and cholesterol: 67 years (40-100
years, ± 11.85). Majority of the study sample belonged to 60-80 years of age and had PDC
values ranging from 90-100 in both pre-period and post-period for all the three drug classes.
Average post-period PDC (0.99) was higher than average pre-period PDC (0.94) and was also
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statistically different from each other for all the three drug classes. Increase in the proportion of
adherent patients from pre-period to post-period was witnessed for the three drug classes i.e.,
diabetes (91.07% to 100%), hypertension (89.89% to 98.88%) and cholesterol (90.91% to
98.70%). However this increase was only statistically significant for the hypertension drug class
(p=0.0215). Also, patients in post-period had higher odds of being adherent in post-period as
compared to pre-period for all the three drug classes.
Conclusions: The results indicated that after being enrolled in med sync, medication
adherence generally improves.
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CHAPTER I

1

INTRODUCTION
The problem of non-adherence
Medication non-adherence, or the failure to take medications as prescribed, is one of the
most significant factors limiting the effectiveness of medications in practice.1 Almost two-thirds
of Americans are non-adherent to medications2 and specifically, 50% of patients taking chronic
medications are non-adherent.1 Hospitalizations, morbidity and mortality are some of the
consequences associated with medication non-adherence.
The causes of non-adherence are dynamic and varies by individual. Non-adherence can
be related to age, culture, social background, values, and attitudes. Disease-related factors such
side effects of the medication, treatment duration, frequency of expected intake, and treatment
complexity also impacts patients’ medication taking behaviors. Some external factors
contributing to non-adherence are the relationship between the patient and the physician or the
nurse, support from the family, health care personnel, and friends and also the amount of health
education a patient has.4,5 Financial factors contributing to non-adherence include higher co-pay
and co-insurances.6 This necessitates the need to develop an intervention which is modifiable and
can be tailored for individual patients.1
Due to the various causes of non-adherence, there is no one solution to addressing this
issue. Additionally, some existing interventions that demand multiple visits to the pharmacy by
either the patient or caregiver not only causes inconvenience to the patient but also interrupts the
workflow of the pharmacist. Such interruptions can lead to declines in medication dispensing
rates and gaps in the medication therapy further causing non-adherence.7
2

Addressing adherence with medication synchronization
An ideal adherence intervention should be one that addresses the multidimensional and
dynamic nature of non-adherence. It should be able to improve access to care, be more
convenient, educate the patients, and provide constant reminders. It should also help the patient
monitor their own improvement and help them engage in mutual problem solving.1
One of the most recent proposed methods to address the above-mentioned issues in nonadherence is medication synchronization (med sync). Med sync is essentially refill
synchronization. It is a process by which multiple chronic medications are refilled at the same
time one day of the month instead of throughout the month.1
With med sync, the focus of the pharmacy staff changes from filling the prescription
reactively upon the sudden request of the patient, to a more organized, synchronized and active
pick-up or delivery of the prescription. This is a patient centric pharmacy care model, different
from the traditional drug centric model.8 This patient centric care model, emphasizes the
preferences, values and needs of the patient. It means that the patient will participate actively in
the shared decision making process.9
Study significance
Adherence plays a crucial role in the Centers for Medicare and Medicaid Services’
(CMS) Star Rating system which is designed to assist Medicare beneficiaries in plan selection.
Among the five measures used by CMS and Pharmacy Quality Alliance (PQA) for calculating
the Star Rating, three of them are related to the medication adherence, therefore making
adherence improvement a high priority.7 With the development of the Medicare Star Rating
System and the increase of commercial Part D plans, it becomes crucial to monitor the adherence
subsequent health outcomes.3 This implies that more empirical research is required to measure
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adherence as a result of synchronization. Limited research has examined this phenomenon as
only two studies have examined the impact of synchronization on adherence, using a matched
cohort design and quasi-experimental study in which study patients were matched with control
patients.1,10 The current study had a pre-post research design, to strengthen the adherence
literature related to medication synchronization.
Study objectives
The specific objectives of this study were to:
Assess the impact of medication synchronization on medication adherence for the following
CMS Star Rating system drug classes:
1. Oral diabetes medications which include biguanides, sulfonylureas, thiazolidinediones,
DPP-IV inhibitors, and meglitinides;
2. Hypertension medications which include renin-angiotensin system antagonists (RASAs)
which includes angiotensin converting enzyme inhibitors (ACEs), angiotensin receptor
blockers (ARBs); and
3. Cholesterol medications which includes statins.
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CHAPTER II

5

LITERATURE REVIEW
Defining medication adherence
Before discussing how non-adherence might be addressed with med sync, it is important
to first define medication adherence, and differentiate it from “compliance” and “persistence”.
Medication compliance is defined as “the extent to which a patient acts in accordance with the
prescribed interval, and dose of a dosing regimen” and can be demonstrated when a patient’s
prescriptions are dispensed on a regular basis as prescribed by the physician. Whereas,
persistence is defined as “the duration of time from initiation to discontinuation of therapy” and
is a continuous variable represented by the total number of days for which the therapy was
accessible. These terms sound similar but they are different because the clinical outcomes of the
therapy depends upon both the medication as well as the duration for which the medications are
consumed.11 The difference between adherence and compliance is that compliance is considered
to be passively following the instructions given by the physician whereas adherence occurs when
both the patient and physician have mutually agreed upon the medication regimen.12
The problem of non-adherence
Looking at the case of chronic disease, non-adherence is a critical issue as almost 133
million people are suffering from at least one chronic disease in the US. Fifty percent of patients
do not take their medicines properly, and 31% of them never get their original prescription
filled.13 Non-adherence can lead to problems such as medication ineffectiveness, increases in
healthcare spending, hospitalizations, and emergency room (ER) visits.12 It has been reported
that non-adherence causes almost 125,000 deaths in the US and incurs a cost of $177 billion
6

annually.14 Chronic diseases such as hypertension, diabetes, hypercholesterolemia and
congestive heart failure (CHF) are among the most prevalent, costly, or both; therefore
addressing medication adherence related to these disease states becomes critical.13
With regard to persistence, adherence achieved in chronic disease states have been
reported to worsen, dropping after the initial 6 months of the therapy itself. In clinical trials,
adherence tends to be more ideal than world scenarios, even then, adherence achieved in chronic
illness patients is low, ranging from 43 to 78%. The consequences of non-adherence are
significant, including exacerbation of the disease, higher mortality, increased healthcare costs,
and increased hospitalizations. Thirty-three percent to 69% of hospitalizations in the US are
attributed to non-adherence and incur $100 billion annually.12
The causes of non-adherence
The six patterns of medication taking behavior found among patients with chronic
illnesses helps to explain the prevalence of non-adherence. One-sixth of patients attain near
perfect adherence; one-sixth consume almost all the doses but at irregular times, one-sixth
occasionally skip single day doses and take doses at irregular times, one-sixth take drug holidays
about 3-4 times in annually while skipping doses occasionally, one-sixth take drug holidays
every month with and skip medications frequently, and one-sixth consume few or no doses while
trying to appear as though they are adherent.12
The causes of non-adherence are many and varied. The World Health Organization
(WHO) has classified five factors as major underlying causes for non-adherence. The first factor
includes individual characteristics such as physical condition, cognitive abilities, and
demographics such as age, gender and race. The second factor includes a patient’s medical
condition including asymptomatic condition and comorbidities. The third factor includes the

7

health system in which the patient lives and the type of care the patient receives. The fourth
factor includes the complexity of therapeutic regimen and fifth factor includes all the
socioeconomic barriers patient faces. Osterberg goes on to note that non-adherence factors
include complicated therapeutic regimens, improper explanation of benefits and side effects of
the medication, lack of concordance with patient lifestyles, and poor patient-physician
relationships.12
Outcomes and costs of non-adherence in chronic disease
As previously discussed, chronic diseases are victim to the issue non-adherence the most.
Considering the example of diabetes mellitus, non-adherence is one of the most prevalent issues
leading to unfavorable outcomes. In a study, the unadjusted analysis states that diabetic nonadherent patients have higher percentage of having all cause hospitalization (23.2% vs 19.2%, p
< .001) and all-cause mortality (5.9% vs 4.0%, p < .001) as compared to adherent patients. It has
also been observed that less than half of the patients consuming statin medications remained
adherent to the therapy after 12 months of starting the therapy. Results of a multivariable
analysis of this study was in agreement with the results above. Increased risk for all cause
hospitalization (OR, 1.58; 95% CI, 1.38-1.81; p < .001) and all-cause-mortality (OR, 1.81; 95%
CI, 1.46-2.23; p < .001) was observed. Cumulative results were consistent with the results of the
individual categories such as oral hypoglycemic, antihypertensive and statin medications. It was
found that with a 25% rise in adherence of antihypertensive medications, an associated decrease
of -1.0mm Hg and -1.2 mm Hg in systolic and diastolic blood pressure was observed. Similarly,
with a 25% increase adherence to oral hypoglycemic and statins a reduction of -0.05% and 3.8mg/dL was observed in HbA1c and LDL-C levels respectively. In this study combined
reduction in the magnitude of hospitalization and mortality was higher than what was anticipated
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given the changes in the intermediate measure. This indicates that adherence might also be
related to self-care behaviors that may or may not be directly related to the final outcomes.
Looking at the importance and consequences of non-adherence, we can conclude that medication
adherence should be assessed by the healthcare providers on a regular basis.15
The systematic literature also indicates that due to non-adherence to oral hypoglycemic
medications, only 43% of the diabetic patients have glycosylated hemoglobin levels under 7% as
recommended by American Diabetes Association. For hypoglycemic agents, a range of 13% to
64% was found for total number of non-adherent patients.16 Lower levels of Medication
Possession Ratio (MPR), a measure of medication adherence was also found to be correlated
with higher costs. MPR can be defined as “Ratio of the number of days’ supply dispensed to a
patient, divided by the number of days in the cohort period, typically a year”. MPR of 60% is
found to be associated with mean total cost of $8,699. Whereas, a 10% increase in the MPR can
be correlated to reduction of 8.6% in total annual healthcare costs. It has been noted that HbA1c
levels lesser than 8% and HbA1c greater than 10 incurred a cost of $4,475 and $8,088,
respectively.14,16 Financially, incident cases are more expensive than prevalent cases and
gestational diabetes cases are more expensive than type-2 diabetes cases.16 These findings
strongly emphasizes on the importance of medication adherence with respect to both healthcare
cost and healthcare utilization.
Bolstering the above findings, another study focusing on the causal link between
medication adherence and health care use and cost for four vascular diseases (hypertension,
diabetes, dyslipidemia, and congestive heart failure (CHF)) was conducted. Results indicated that
although increase in medication adherence causes an in increase total pharmacy costs, it helps in
saving a substantial amount of money by reducing overall expenditure in hospitalizations
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particularly linked with inpatient hospital days and ER visits. Hospitalizations and ER visits are
of priority as they are the key drivers of healthcare costs. Results indicate that adherence in
dyslipidemia and CHF can be associated with fewer inpatient hospital days, ranging from 1.18
fewer days to 5.72 fewer days respectively. The average benefit-cost ratio due to medication
adherence for CHF, hypertension, diabetes and dyslipidemia can be given as 8.4:1, 10.1:1, 6.7:1
and 3.1:1 respectively. Financial gains resulting from better adherence truly justifies adopting
adherence management programs that can lead to considerable medical savings. Results also
recommend the use of pharmacist-led patient counseling as a promising intervention to improve
adherence at lower expenses.13
Another study evaluating the impact of adherence on healthcare utilization and cost for
diabetes, hypertension, hypercholesterolemia and CHF was performed. For diabetes and
hypercholesterolemia, low disease-related medical costs were found to be correlated with higher
levels of medication adherence and these higher levels were associated with significantly fewer
hospitalizations. For hypertension, hypercholesterolemia and diabetes, pharmacy cost was offset
for all-cause medical cost at relatively higher levels of medication adherence. It can be inferred
that benefits gained due to increased prescription drugs (due to improved adherence) is worth the
added cost.17
Another study was conducted focusing on finding the association between medication
adherence and utilization for acute healthcare services. Results of logistic regression analyses
suggested that adherence was a significant predictor of all-cause hospitalizations and ER visits. It
was observed that chances of all-cause hospitalization and ER visits among the adherent patients
were 40% less in patients with diabetes, 44% less in patients with hypercholesterolemia and 35%
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less in patients with hypertension. These findings imply that policy makers should focus on
interventions that can improve adherence leading to other benefits.18
Addressing non-adherence
Considering the importance of adherence in a multidimensional aspect, it becomes crucial
to employ interventions that can improve adherence which can lead to reduction in total
healthcare cost. One of the most crucial reasons to focus on adherence comes from the Centers of
Medicare and Medicaid Services (CMS). CMS evaluates Medicare Part D plans on the basis of
Star Rating system ranging from one to five stars. Star Rating consist of four sections, one of
which is categorized as pricing and patient safety. This section consists of measures evaluating
medication adherence for oral diabetes agents, hypertension agents and cholesterol agents. Star
Rating are useful in making quality based payments to Medicare Advantage Plans (MA-PDs)
and selling benefits to prescription drug plans (PDPs).19
As stated in a Chain Drug Review article, MA-PDs cannot achieve the five-Star Rating
without active and effective participation from community pharmacies that create quality patient
outcomes.19 In agreement, the 2012 WHO report stated that interventions aiming at improving
medication adherence are more capable of improving health of people than any other medical
intervention.19 It has been reported that that five out of every six pharmacist directed adherence
interventions can improve the adherence of patients ranging from 7% to 27%. Pharmacist-led
interventions have approximately 83% successfully adherent patients as compared to 67%
adherent patients in electronic interventions with no involvement of humans, 38% adherent
patients in phone calls lead interventions and 38% adherent patients involved in clinic programs
making the role of pharmacists important in the adherence management program.1 Interventions
that can help to reduce wait times and improve the communication between physicians and
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patients could be more beneficial. Patients who often miss their appointments are those who may
require assistance the most to become adherent. They can be helped by providing increased
information, motivation and imparting behavioral skills.12,20
Considering the dynamic and multidimensional nature of medication adherence,
especially in chronic diseases as stated above, medication synchronization (med sync) may be a
solution to managing medication adherence. Med sync is a process of coordinating multiple
chronic medications of a patient to be picked-up or delivered on one day each month.1 There
are several med sync programs available on the market such Elite Care, MedSync,
SyncYourMeds, HealthyPackRx, RxSync, SimplifyMyMeds, TimeMyMeds and the
Appointment Based Model (ABM).
Medication synchronization – how it works
One of the major steps of the med sync process is to identify ideal patients for the
program. Patients using multiple chronic medications and making multiple visits to the
pharmacy in a month are the best fit for the program. Multiple monthly visits made by the patient
to the pharmacy should be taken into consideration. Patients who visit the pharmacy multiple
times per month to maintain their social network may not be good candidate for med sync.21
Once a patient is deemed a good candidate for med sync, the anchor drug must be
identified. An anchor drug is defined as the drug around which the first synchronization date is
identified.1,21 The cost of the drug, amount of co-pay and out-of-pocket costs are among the
various deciding factors for the anchor drug selection.7
Selection of the chronic drugs to be synchronized is another important component in the
initiation of the program. Not all the chronic drugs are eligible for the inclusion in the program.
Chronic drugs such as sedative hypnotics, anxiolytics and analgesics are not recommended for
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the enrollment in the synchronization process. Other chronic medications inappropriate for the
synchronization includes those with non-standardized doses such as insulin, creams, eye drops
and inhalers and drugs with varying cycles such as bisphosphonates, oral contraceptives and
vitamin D. Pre-written Schedule II prescriptions and medications in unbreakable packaging are
not good candidates for synchronization. Drugs treating hypertension, diabetes, and
hypercholesterolemia are among the suitable candidates.7
While selecting first synchronization date, the pharmacist should provide patients with
short fills and long fills depending upon the doses remaining on the patient’s current
prescriptions. Short fills are for a less than usual supply whereas long fills are dispensing
medication more than the typical supply.8 This avoids disruption in the continuity of therapy.1
Alternatively, the pharmacist or technician may contact the physician to reauthorize all new
refills for a patient for 28 or 30 days. Once the drugs to be synchronized are decided, they are
documented in a pre-appointment call sheet.
A week before the appointment day the pharmacist or technician calls the patient to check
about changes in the medication regimen, if any. This call differentiates med sync from other
automatic refill programs as it is an opportunity to gain meaningful information about the patient
which is not possible during an automated call.8 Additionally, it develops a sense of being cared
for in the patient’s mind and the perception that a complete health system is attempting to help
them to have a healthier life.8 Additionally, the pharmacist or technician identifies any problems
with medication adherence and any medical issues of concern. Once the call is complete, the
pharmacist or technician adjudicates and processes the prescriptions in preparation for filling the
prescriptions. Any insurance related issues are also resolved at this time.
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Three days before the appointment day, the pharmacist or technician fills the prescription
for subsequent pick-up or delivery. The day before the prescription is due or even that day,
depending upon the preference of the patient, the medication is either collected by them or is
delivered to them by the courier (or mail service if delivered earlier).22 In some med sync
programs, patients who fail to pick-up their medication on the pick-up day are contacted by the
pharmacist.21
Physicians play a critical role throughout the process. It is the responsibility of the
pharmacist to inform the physician if their patients enroll in med sync. A formal letter should be
mailed to the physician with a request to refill the synchronized medications.1,7 Communication
with the physician helps the physician gain additional information about the patient who is
enrolled in med sync.
Benefits of medication synchronization
Benefits to patients. Med sync is argued to be beneficial in improving the overall
adherence of a patient in several ways. Fewer number of pharmacy visits may lead to better
medication adherence and promote continuity of care, thereby improving access to care.1 Unlike
traditional, reactive, prescription filling, med sync prescriptions get filled within a week of the
pick-up or delivery date leading to reduction in medication gaps and unavailability of medicines.
By the time patient reaches the pharmacy to pick-up their medication their insurance has already
been processed resulting in more convenience.1 In some med sync programs, the monthly
appointment with the pharmacist gives the pharmacist an opportunity to clarify, modify, and
enhance the patient’s medication therapy leading to a reduction in possible medication errors.1
Monthly phone calls (and appointments, if used) helps the pharmacist educate the patient and
involve them in solving drug-related and adherence problems related to lack of affordability,
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physical impairment, low health literacy and shortage of social support. Synchronization
simplifies the medication regimen and provides constant progress updates and feedback to the
patient and the patient’s physician.1,3
Med sync helps manage medications with greater therapeutic complexity, leading to
improved outcomes.1 Synchronization takes care of the preference of the patient with regard to
the payment, delivery and mode of contact as well. Patients have the choice to either pick up
their medication or receive it by mail or courier. They can pay for the medication by either a
single monthly payment or have the option to split it up in several monthly installments. Patients
can be contacted by cell phone, home phone or even email.1
Benefits to pharmacists. Med sync allows the pharmacist to step out from behind the
counter and provide patients with the healthcare and clinical services they require. Better
management of pharmacy work flow is an advantage as everything taking place at the pharmacy
is pre-planned and proactive. The frequency of phone calls is reduced as the system is more
structured, yielding substantial time savings and more organized staff.3 It improves the overall
business in the pharmacy by increasing the prescription revenue and gives an opportunity to
provide Medication Therapy Management (MTM) services and additional clinical services like
immunizations and flu shots.1 Med sync also reduces the total number of random visits made by
the patients, which helps in managing the disorder in the pharmacy and also helps to reduce the
stress levels of the pharmacist working there.8 To summarize, med sync promotes the
achievement of overall operational efficiency of the pharmacy.21
Med sync allows the pharmacist to better perform in their role as a healthcare provider.
They can offer suggestions regarding over-the-counter medications and guide the patient towards
a better diet, lifestyle changes and needed home equipment.3 It also allows the pharmacist to
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provide Medication Therapy Management (MTM) services to the patient, and possibly be
reimbursed for these services. As an added advantage, the outcome data collected in this process
are often used to incentivize pharmacists which motivates pharmacists to perform better.8
In terms of business, med sync can give fruitful returns for the invested labor. Findings
state that prescription revenue has gone up by 29% for patients who are associated with the
pharmacy for a year or more by using Elite Care which is a med sync program offered by Red
Cross pharmacy.3
Benefits to physicians. Physician-pharmacist communication that occurs when enrolling
patients for med sync serves as opportunity to educate the physician about the advantages of med
sync and gather support from them.7 The literature suggests that physicians are pleased with med
sync programs and improvement in medication adherence, and receiving feedback related to
adherence.21 As stated by a pharmacist based in Colorado, with the help of med sync programs,
pharmacists have taken the time consuming part of the physician’s job, and that physicians truly
appreciate it.8
Challenges of medication synchronization
The challenges associated with med sync include identifying and enrolling patients,
identifying anchor dates and drugs, differentiating sync patients from the non-sync patients,
managing short-fills and long fills.2 While dispensing short fills and long fills to reach a sync
date, the pharmacist needs to address insurance issues as well. Because all of a patient’s
prescriptions are being dispensed on the same date, the pharmacist needs to manage and
calculate the co-pays carefully. This can be more difficult when dealing with Medicare Part D
patients who are moving into the donut hole21 and Medicaid patients who may have a
prescription cap. Pharmacists should make patients aware of the possible one-time cost

16

associated with the co-pays and out-of-pocket costs related to the short fills received just before
the first sync date.7
Considering that the role of pharmacist is crucial in the successful implementation and
maintenance of med sync, pharmacists and their staff need to be constantly educated on a regular
basis. Educational materials may include modules related to patient centered care, prescription
synchronization techniques, maintenance of proper documentation, methods to foster mutual
problem solving, and providing MTM services. Having improved and efficient technology might
also results in easier implementation and scalability of med sync helping in creating and storing
data which can be of help to prove the program’s worthiness in the future.
Med sync research findings
In a study conducted by a joint collaboration of the National Community Pharmacists
Association (NCPA) and Ateb Inc., investigators measured the impact of Ateb’s Time My Meds
synchronization program on medication adherence. They created a study group and matched it
with a control group. Results indicated that Time My Meds made a substantial improvement in
the medication adherence of the patients and also helped in increasing the pharmacy’s revenue
and total gross margin.10
Another study was conducted by Virginia Commonwealth University (VCU) with Thrifty
White Pharmacy, a chain of employee-owned community pharmacies. In this study, the
Appointment Based Medication (ABM) med sync model was used. Investigators utilized a quasiexperimental research design while matching the study patients to the control. It resulted an
increase in the adherence of the patients and also showed a decreased probability of nonpersistence. Specifically, it was reported that by increasing a diabetic patient’s medication
adherence from 40-59% $4,091 can be saved per patient.3 With 25.8 million diabetic patients in
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the US, the amount of savings could be phenomenal. This study also reflected an increased level
of adherence among study patients as compared to the control patients. Patients enrolled in the
med sync had adherence rates of 66.1%-75.5% as compared to the control patients with 37%40.8% for initial one year. In terms of odds of adherence, study patients had 3.4-6.1 times higher
odds of adherence compared to control.1 A follow-up study conducted for Thrifty White’s study
displayed increased adherence with med sync program. It resulted in a significant drop in the
cost of healthcare with patients having hypertension, diabetes and increased cholesterol levels.22
Due to med sync’s positive results and improvement in adherence, almost 250-350
people a week enroll in med sync at Thrifty White Pharmacy. Most of the patients enrolled in the
study were 40 to 55 years old. People in this age group are those who are working and have a
busy schedule. Providing reminders for their medication can be helpful for them to maintain their
health in their hectic life style. Overall, med sync has been successful in yielding positive results
by improving medication adherence of patients. This is well reflected in both patient satisfaction
surveys as well as the talks done with the payers.22
Summary
These findings combined with the importance of medication adherence for the healthcare
system makes further empirical examination of med sync an important step toward better
medication use outcomes and lowered healthcare spending. In fact, state legislatures are
recognizing this importance. For example, Missouri was one of the first states to propose a bill
stating that pharmacies providing medication synchronization should be reimbursed for the short
fills dispensed for the reason of synchronization.23 Continued research using alternative study
designs are necessary for understanding the role of med sync in medication adherence
management.
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METHODS
Study design
A quasi-experimental pre-post study design was employed for this study using pharmacy
prescription fill data from various independent community pharmacies located in different
regions of Mississippi. Patients were compared on the main outcome measure, medication
adherence, before and after the medication synchronization intervention. Because this study
employed a pre-post study design, patients served as their own control.
A six month pre and post study period was used to measure adherence. Analyses were
conducted separately for each of the drug classes under the CMS Five-Star Quality Rating
System. Drug classes in the CMS Five-Star Quality Rating System include oral diabetes
medications, hypertension medications and cholesterol medications.
The total study period for each patient was one year, including the pre- and post-study
period. Patients’ medication adherence was calculated for a six month period before the index
date and a six month period after the index date. The index date was used to separate the pre- and
post period of each patient. Index date was defined as the first med sync date when the patient
received his first fill of the prescription after enrollment in the med sync program. Index date
(also termed med sync date) was agreed upon by the pharmacist and the patient, and on this date
all prescriptions were dispensed at the same date every month. Each patient was flagged on their
specific index date in the data indicating the start of the med sync program. This flag was used to
separate the pre and post intervention period. The post period of six months was a part of the
treatment period. Treatment period was defined as time beginning from the index start date
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(ISPD) until the last day of post period or end of measurement period or until death or
until discontinuation from the med sync program. This study received an approval from the
Institutional Review Board (IRB) of The University of Mississippi.
Data extraction
Pharmacy prescription fill data was collected for the dates January 1, 2008 until the date
investigators visited the pharmacy (hereafter called as the measurement period). Med sync
patients were identified until the time each patient had sufficient post period of six months so as
to have a sufficient time frame to measure post period (post-index date) medication adherence
for enrolled patients. Each patient had their own index date and based upon that a unique and
separate pre-post period.
Sample description
A convenience sample of independent community pharmacies practicing medication
synchronization was used for identifying med sync patients. Selected pharmacies were situated
in various regions of Mississippi therefore reducing the geographical bias. All med sync patients
having a prescription fill history in the measurement period within each pharmacy and satisfying
the inclusion and not eliminated by exclusion criteria (described below) were used for analysis.
Table 1 outlines a convenience sample of independent community pharmacies used for
the study. Before extracting data from the pharmacies, a Data Use Agreement (DUA) was also
executed between each pharmacy and the University of Mississippi. All patients having a
prescription fill history in the measurement period within each pharmacy were taken. While
performing the analysis patients meeting the inclusion criteria and not eliminated by exclusion
criteria (described below) were used.
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Table 1: Convenience Sample of Pharmacies
Store name

Pharmacist contact

City

Gene Polk’s Pharmacy

E. Brinson Polk, Jr.

Magee

Iuka Discount Drugs

Chris Cornelison

Iuka

Thrift Drugs

Marty Bigner

McComb

Tyson Drug Co

Bob Lomenick

Holly Springs

Inclusion criteria
Patients were enrolled in med sync program offered by their pharmacy. Patients at least
18 years of age were included in the study. Every patient taking prescription medications
belonging to the following drug classes were included in the analysis: Oral diabetes medications
which included biguanides, sulfonylureas, thiazolidinediones, DPP-IV inhibitors and
meglitinides; hypertension medications which included renin-angiotensin system antagonists
(RASAs), angiotensin converting enzyme inhibitors (ACEs), angiotensin receptor blockers
(ARBs); and cholesterol medications which included statins. Patients taking these medications in
oral dosage form, only, were included in the analysis. Patients had to have an index date in order
to meet the requirements of a pre-post design. Patients having a continuous prescription history
of at least 180 days (six months) before and after the index date were included in the analysis.
Exclusion criteria
With regard to prescription transactions, records for insulins and incretin mimetics
(administered by subcutaneous injection), were removed before analysis due to inability to
synchronize refills of these medications. Patients having a continuous gap equal to or more than
90 days during the observation period were also excluded assuming that they have discontinued
taking the medications. Also, patients having missing values for age or date of birth were
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removed from the analysis. This was done in order to comply with the IRB regulations of
including patients only with greater than or equal to 18 years of age.
Sample size
Wilcoxon Signed-Rank Tests was performed in order to assess any changes in
medication adherence from the pre-period to the post-period. Sample size requirements for
Wilcoxon Signed-Rank Tests were calculated using G*Power. According to result obtained by
G*Power, a total sample size of 82 patients (number of pairs) was needed in order to perform a
Wilcoxon Signed-Rank Tests with a medium effect size of 0.3 and alpha level of 0.05 to obtain
a power of 80% assuming we use minARE as the parent distribution. When the parent
distribution is unknown, then “minARE” is used as the parent distribution while performing the
sample size calculations. Also, the value of effect size (0.3) was chosen for this test. It is the
standard value used to obtain a medium effect size which can be used for sample size
calculations for the Wilcoxon Signed-Rank Test for matched pairs.24 Considering the analysis
was be performed separately for the three drug classes, we required 82 patients’ pairs in each of
the drug classes for the analysis. A brief synopsis of the above sample size calculations for
Wilcoxon Signed-Rank Test for paired data is provided in Table 2 below:
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Table 2: Sample Size Calculation for Wilcoxon Signed-Rank Test for Paired
Data
Alpha

Power

Medium

Distribution

Effect Size

Total Sample
Size (N= # of
pairs)

Diabetes

0.05

0.8

0.3

minARE

82

Hypertension

0.05

0.8

0.3

minARE

82

Cholesterol

0.05

0.8

0.3

minARE

82

When assessing the study outcome, patients having a PDC greater than or equal to 80%
were considered “adherent” and patients having a PDC less than 80% were considered “nonadherent”. A dichotomous flag variable was created by flagging adherent patients as “1” and
non-adherent as “0”. The proportion of individuals who were adherent was calculated for the
pre- and post- periods using this dichotomous flag variable. In order to assess the significance of
the difference between two correlated proportions, McNemar’s Test was performed. G*Power
was used for sample size calculations for this analysis test, and sample size calculations were
calculated separately for the three CMS Star Rating system drug classes. In order to calculate
sample size, the value of the proportion of discordant pairs and odds ratio of being adherent in
post period as compared to pre period in the G*Power was needed. Discordant pairs are those
patients who are adherent in pre-period and non-adherent in post-period (“Adherent”~“NonAdherent”) OR those patients who are non-adherent in pre-period and adherent in post-period
(“Non-Adherent” ~“Adherent”). Whereas, concordant pairs are those patients who are adherent
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in pre as well as post period (“Adherent” ~“Adherent”) OR those patients who are nonadherent in pre- as well as post-period (“Non-Adherent” ~“Non-Adherent”). The proportion of
discordant pairs can be calculated by the sum of the proportion of discordant pairs in pre-period
(Ppre) and the proportion of the discordant pairs in post-period (Ppost) i.e. PD= (Ppost +Ppre).
Considering data was not collected at the time of sample size calculations, the values of the
proportion of discordant pairs in pre-period (Ppre) and post-period (Ppost) were unknown, the
following approximation formula was used to calculate proportion of discordant pairs (PD): Pt
(1-Ps) + Ps (1-Pt). Where, Pt is the proportion of adherent patients in post-period and Ps is the
proportion of adherent patients in pre-period. This provided an estimate of the PD for the sample
size calculation. The odds ratio was calculated by dividing the proportion of discordant pairs in
post-period by the proportion of discordant pairs in pre-period, i.e., Ppost/Ppre. It is proved that,
Pt=Ps is equivalent to Ppost=Ppre, therefore the odds ratio was calculated by Pt/Ps.25


Oral medications including biguanides, sulfonylureas, thiazolidinediones, DPP-IV
inhibitors, and meglitinides. According to the performance scores calculated on Mississippi
Medicare data for the year 2007, approximately 18.20%, 33.3% and 41.5% patients (18
years and older) were found to be adherent (meeting PDC threshold of 80%) to oral diabetes
medications (Thiazolidinediones, Biguanides and Sulfonylureas respectively). According to
guidelines given by the CMS Star Rating system (Prescription Drug (Part D) Plans, i.e.,
PDP) a pharmacy needs to have a percentage of adherent patients between ≥ 79% and <
82% in order to achieve 3 stars in the CMS Star Rating system. For the purpose of this
analysis the proportion of adherent patients in the pre-period was assumed to 0.182, 0.333
and 0.415 (Ps) for Thiazolidinediones, Biguanides and Sulfonylureas respectively and
proportion of adherent patients in the post period is assumed to be 0.8199 (Pt). The
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proportion of discordant pairs (PD) was 0.7034564, 0.6068466 and 0.554383 and odds ratio
was 4.504945055, 2.462162162 and 1.975662651 for Thiazolidinediones, Biguanides and
Sulfonylureas respectively (calculated using the formulas listed above). Using these values
and alpha level of 0.05 and a power of 0.80; 19, 58 and 109 pairs were required to perform
the original McNemar’s Test. Taking these sample sizes into consideration, a conservative
estimate of 109 pairs was required for the purpose of analysis of oral diabetes medications
drug class.


Hypertension medications including ACEs/ARBs: According to the performance scores
calculated on the Mississippi Medicare data for the year 2007, approximately 40.00%
patients (18 years and older) were found to be adherent (meeting PDC threshold of 80%) to
hypertension medications (ACEI/ARBs). According to guidelines given by the CMS Star
Rating system under the PDP, a pharmacy needs to have percentage of adherent patients
between ≥ 76% and < 81% in order to achieve 3 stars in the CMS Star Rating system. For
the purpose of this analysis the proportion of adherent patients in the pre-period was
assumed to be 0.40 (Ps) and proportion of adherent patients in the post period was assumed
to be 0.8099 (Pt). The proportion of discordant pairs (PD), i.e., 0.56198 and odds ratio, i.e.,
2.02475 was calculated using the formulas listed above. Using these values and alpha level
of 0.05 and a power of 0.80; 95 pairs were required to perform the original McNemar’s Test.



Cholesterol medications including statins: According to the performance scores calculated
on the Mississippi Medicare data for the year 2007, approximately 28.90% patients (18 years
and older) were found to be adherent (meeting PDC threshold of 80%) to cholesterol
medications (statins). According to guidelines given by CMS Star Rating system under the
PDP, a pharmacy needs to have percentage of adherent patients between ≥ 69% and < 75%
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in order to achieve 3 stars in the CMS Star Rating system. For the purpose of this analysis
the proportion of adherent patients in the pre-period was assumed to be 0.289 (Ps) and the
proportion of adherent patients was assumed to be 0.7499 (Pt). The proportion of discordant
pairs (PD), i.e., 0.6 and odds ratio, i.e., 2.6was calculated using the formulas listed above.
Using these values and alpha level of 0.05 and a power of 0.80; 50 pairs were required to
perform the original McNemar’s Test. Calculations for the original McNemar’s Test are
provided in Table 3 below:

Table 3: Sample Size Calculation for McNemar’s Test
Post

Pre

Proportion

Odds

Alpha

Power

Total

Period

Period

of

Ratio

(Pt)

(Ps)

Discordant

Size (N=

Pairs (PD)

# of pairs)

Sample

Diabetes

0.8199

0.415

0.554383

1.98

0.05

0.80

109

Hypertension

0.8099

0.40

0.56198

2.02

0.05

0.80

95

Cholesterol

0.7499

0.289

0.6054578

2.60

0.05

0.80

50

Data collection
Study investigators visited the pharmacies to collect data for this study. A DUA was
executed between each pharmacy and the University of Mississippi before data collection. All
the prescription fill data was transferred from the computer system to a flash memory drive. As
soon as the data was collected, the patient identifiers were converted into a de-identified format
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by encrypting the patient identifiers assigned by the pharmacy. All Data File(s) were
installed on a secure, stand-alone, non-networked access computer maintained in the School of
Pharmacy, housed in a secure Center for Pharmaceutical Marketing and Management (CPMM)
Data Center. The study was approved by the Institutional Review Board (IRB) of The University
of Mississippi.
Data management
All the pharmacy data was pulled, cleaned, processed and analyzed with the help of
Statistical Analysis Software 9.4 (SAS®, SAS Institute, Cary, NC). Based on the National
Drug Code (NDC) of the drugs; prescription records were assigned to their respective therapeutic
classes as classified by CMS Star Rating system. Detailed list of all the drugs with their NDCs,
which are included in the PQA Measure of Proportion of Days Covered (PDC) for oral diabetes
medications, hypertension medications and cholesterol medications was used for the purpose of
this study. All the original collected data was stored on the secured server in order to maintain
the security and privacy of the data and participating individuals. Patient identifiers were
converted into an encrypted format by de-identifying the patient identifiers. Later in the analysis,
patients were identified in the pharmacy database with their help of their de-identified patient
identifiers. Patients were identified as a part of the med sync program with the help of their index
date specified by the pharmacist.
Measures
Proportion of days covered (PDC) was used to calculate the adherence of patients in
the study. PDC is the preferred measure of adherence by the PQA. The mathematical
formula PDC is given as below:
PDC = Number of days the patient is covered by the drug in the study period
Number of days in the study period
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PDC helps to achieve a conservative estimate of the medication adherence especially when
a patient consumes more than one medication for their treatment. Considering the current
study focusing on med sync, whereby the patients of interested consumer more than one
chronic prescription drug per month; the use of PDC as an adherence measurement became
more relevant. PDC is always helpful in adjusting for the gaps in therapy and also
adjusting for overlap in therapy. While doing the calculations for PDC, a day is only
counted if the patient has medication in his or her possession. PDC values can range from
zero to one. The assumption that we make while using such a measure, is that, when a
medication is possessed the medication is assumed to be consumed as well.26 Patients
having PDC equal to or greater than 0.80 were considered adherent. According to the
measure, if multiple prescriptions for the same generic drug are given on the same day or
different days with overlapping days’ supply, adjustment should be made to the
prescription start date, so that the start date for the same second generic drug is the day
after the previous fill has ended. Same adjustment was performed while calculating the
PDCs for the study participants.
Data analyses
Data analysis was conducted using SAS software (version 9.4; SAS Institute, Cary, NC).
Descriptive statistics of the sample after applying inclusion-exclusion criteria were calculated
for each of the therapeutic drug classes separately. Descriptive statistics included calculating
means, frequencies and percentages as appropriate.
For assessing study objectives, PDC scores for the pre and post periods for each patient in
the study were calculated. Patients having a PDC value of 0.80 or more were considered
“adherent” and PDC less than 0.80 were considered “non-adherent”. A dichotomous flag
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variable was created, in which adherent patients will be flagged as “1” and non-adherent patients
were flagged as “0”. Because this study uses a pre-post design, patients served as their own
control. Patients’ PDC values before and after the index date were calculated. Mean and median
PDC scores of pre and post periods for each of the three CMS drug classes were obtained.
Considering the paired nature of the observations and non-normality of the PDC scores
(proportion), Wilcoxon Signed-Rank Test for paired data was used to compare the PDC scores of
pre and post periods for each of the three drug classes separately. An alpha level of 0.05 was
used for the Wilcoxon Signed-Rank Test for the paired data, obtaining a p-value lesser than 0.05
lead to the rejection of the null hypothesis helping us to infer that the pre-period and post-period
scores are statistically different from each other. Secondly, the proportion of adherent patients in
the pre-period was compared to the proportion of adherent patients in the post-period for each of
the three therapeutic drug classes separately. In order to calculate this proportion, the numerator
included all those patients meeting the inclusion/exclusion criteria and flagged as “1”. Whereas,
the denominator included all those patients meeting the inclusion/exclusion criterions and
flagged as “1” or “0” both. An alpha level of 0.05 was used for this test, obtaining a p-value
lesser than 0.05 lead to the rejection of the null hypothesis and helped us to infer that the
marginal proportions are significantly different from each other. After performing the
McNemar’s Exact Test a 2x2 contingency table was obtained to calculate the odds of adherence
in the post-period as compared to the pre-period. McNemar’s Exact Test was performed for each
of the three drug classes separately.
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RESULTS
Sample description
Prescription transaction data was collected from Thrift Drugs, Gene Polk’s Pharmacy,
Tyson Drugs Co and Iuka Discount drugs. An initial list of total 126, 139 and 146 synchronized
patients containing index date and enrollment date information was obtained from Gene Polk’s
Pharmacy, Tyson Drugs Co and Iuka Discount drugs pharmacy respectively. Due to the
unavailability of index date and enrollment date information at Thrift Drugs Pharmacy, all of
their prescription transaction data was discarded and Thrift Drugs pharmacy was excluded from
the study. Data from the remaining three pharmacies was combined and patients were assigned
to their respective drug classes by matching the NDC numbers present in their prescription
transaction records with the list of the NDCs provided by PQA for each of their drug classes.
Multiple patients contributed to more than one drug class considering that many of them
were taking multiple drugs belonging to more than one drug category. Separate datasets were
created for diabetes, hypertension and cholesterol categories. Inclusion and exclusion criteria
were applied to each of the drug categories separately for the purpose of analysis.
A total of 56, 89 and 77 patients were found to meet the inclusion/exclusion criteria in
diabetes, hypertension and cholesterol drug categories, respectively. The average age of the
patients was approximately 66 years (23-87 years, ± 11.03), 70 years (41-101 years, ± 11.53) and
67 years (40-100 years, ± 11.85) in diabetes, hypertension and cholesterol drug categories,
respectively. The sample predominantly belonged to those patients who were falling in the age
category of 60-80 years (Table 4).
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Table 4: Distribution of Patients by Age
Age Categories

Diabetes (%)

Hypertension (%)

Cholesterol (%)

18-40

1 (1.79)

0

0

40-60

8 (14.29)

13 (14.61)

19 (24.68)

60-80

43 (76.79)

59 (66.29)

48 (62.34)

80-100

4 (7.14)

15 (16.85)

9 (11.69)

100+

0

2 (2.25)

1 (1.30)

Total

56 (100)

89 (100)

77 (100)

Patient PDC values
Using the prescription transaction data, proportion of days covered (PDC) was calculated
for the pre-period and post-period. Each patient had a unique index date, and depending upon
that index date, their own pre-period and post-period. The results indicate that 47 (83.93%), 67
(75.28%) and 59 (76.62%) patients belonging to the diabetes, hypertension and cholesterol drug
categories, respectively, had PDC values in the range of 90-100 in the pre-period. Whereas in the
post-period, almost 54 (96.43%), 87 (97.75%) and 74 (96.1%) patients belonging to diabetes,
hypertension and cholesterol drug categories, respectively, had PDC values in the range of 90100. Results indicate an appreciable increase in the number of patients whose PDC values were
in the range of 90-100. A full description of the distribution of patients falling in various PDC
categories are presented in Table 5.
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Table 5: Distribution of Patients Belonging to PDC Categories in Pre- and Post-Period

Diabetes
Pre-Period
Post-Period

Hypertension
Pre-Period
Post-Period

Cholesterol
Pre-Period
Post-Period

30-40
(%)

Proportion of Days Covered (PDC) Categories
40-50
50-60
60-70
70-80
80-90
(%)
(%)
(%)
(%)
(%)

1 (1.79)

1 (1.79) 1 (1.79)

0

0

0

0

0

4 (4.49)

0

0

0

0

0

0

0

90-100
(%)

1 (1.79) 1 (1.79) 4
(7.14)
0
0
2
(3.57)

47
(83.93)
54
(96.43)

3 (3.37) 2 (2.25) 13
(14.61)
0
1 (1.12) 1
(1.12)

67
(75.28)
87
(97.75)

3 (3.9)

2 (2.6)

2 (2.6)

0

0

1 (1.3)

59
(76.62)
74
(96.10)

11
(14.29)
2 (2.6)

Patients PDC values categorized by age
A cross-table was also created between age categories and PDC categories in the preperiod as well as the post-period. This information is provided in Table 6 below for diabetes,
hypertension and cholesterol drug categories, respectively. A majority of the patients were
between 60 and 80 years and had PDC values ranging from 90 to 100 during both the periods in
all the three drug categories.
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Table 6: Patient PDC Values Categorized by Age
Age Categories
18-40 (%)

40-60 (%)

60-80 (%)

80-100 (%)

100+ (%)

0
0
0
0
0
0
1 (1.79)

0
0
0
0
0
1 (1.79)
7 (12.50)

1 (1.79)
1 (1.79)
1 (1.79)
1 (1.79)
1 (1.79)
3 (5.36)
35 (62.50)

0
0
0
0
0
0
4 (7.14)

0
0
0
0
0
0
0

Post-Period
80-90 0
90-100 1 (1.79)

1 (1.79)
7 (12.50)

1 (1.79)
42 (75)

0
4 (7.14)

0
0

0
0
0
0
0

0
1 (1.12)
0
0
12 (13.48)

2 (2.25)
1 (1.12)
2 (2.25)
13 (14.61)
41 (46.07)

2 (2.25)
1 (1.12)
0
0
12 (13.48)

0
0
0
0
2 (2.25)

Post-Period
70-80 0
80-90 0
90-100 0

0
0
13 (14.61)

1 (1.12)
1 (1.12)
57 (64.04)

0
0
15 (16.85)

0
0
2 (2.25)

0
0
0
0
0

2 (2.60)
0
0
4 (5.19)
13 (16.88)

1 (1.30)
1 (1.30)
2 (2.60)
5 (6.49)
39 (50.65)

0
1 (1.30)
0
1 (1.30)
7 (9.09)

0
0
0
1 (1.30)
0

Post-Period
70-80 0
80-90 0
90-100 0

1 (1.30)
1 (1.30)
17 (22.08)

0
1 (1.30)
47 (61.04)

0
0
9 (11.69)

0
0
1 (1.30)

Diabetes
Pre-Period
30-40
40-50
50-60
60-70
70-80
80-90
90-100

Hypertension
Pre-Period
50-60
60-70
70-80
80-90
90-100

Cholesterol
Pre-Period
50-60
60-70
70-80
80-90
90-100
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Comparing PDC values between the pre-period and post-period
The objective for this study was to compare the mean PDC values of the patients in preperiod with their PDC value in the post-period.
Wilcoxon Signed-Rank Test: PDC values were calculated for the pre-period and post
period for each patient. A variable was created by subtracting the post-period PDC values from
the pre-period PDC values for each patient. Considering the paired nature of the observations
and non-normality of the PDC scores (proportion), a Wilcoxon Signed-Rank Test for paired data
(alpha= 0.05) was performed separately for each of the drug categories.
Diabetes: An average PDC of 94 ± 0.14 and 99 ± 0.03 was found in the pre-period and
post-period respectively. As a result of this analysis, a Wilcoxon-Signed Rank Test statistic of
143 (p= 0.0001) was obtained. The required sample size for this analysis was 82 patients
whereas the current study had only 56 patients. Therefore sample size requirements were not met
for this test.
Hypertension: An average PDC of 94 ± 0.12 and 99 ± 0.03 was found in the pre-period
and post-period respectively. As a result of this analysis, a Wilcoxon-signed rank test statistic of
391 (p= <.0001) was obtained.
Cholesterol: An average PDC of 94 ± 0.11 and 99 ± 0.04 was found in the pre-period and
post-period respectively. As a result of this analysis, a Wilcoxon-signed rank test statistic of
369.5 (p= <.0001) was obtained. The required sample size for this analysis was 82 patients
whereas the current study had only 77 patients. Therefore sample size requirements were not met
for this test.
The two-tailed p-values generated by the Wilcoxon-Signed Rank Test for each of the
three drug categories was less than 0.05. Therefore, the null hypothesis was rejected and it is
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concluded that statistically significant differences exist between the PDC values in pre-period
and PDC values of post-period for all the drug categories. Results of this analysis are shown in
detail in Table 7.

Table 7: Wilcoxon-Signed Rank Test Results
Drug Class

Pre-Period

Post-Period

Wilcoxon-Signed

P (Two-tailed)

Rank Statistic (S)
Mean (Standard

Mean (Standard

Deviation)

Deviation)

0.94 (0.14)

0.99 (0.03)

143

0.0001*

Hypertension 0.94 (0.12)

0.99 (0.03)

391

<.0001*

Cholesterol

0.99 (0.04)

369.5

<.0001*

Diabetes

0.94 (0.11)

*Significant at α = 0.05

Comparison between proportions of adherent patients in pre-period and post period
In a secondary analysis, the proportion of adherent patients in pre-period was compared
to the proportion of adherent patients in post-period. Adherent patients were those who had a
PDC value greater than or equal to 0.80 and were flagged as ‘1’ and non-adherent patients were
flagged as ‘0’. In order to calculate this proportion, the numerator included all those patients
meeting the inclusion/exclusion criteria and flagged as “1”. Whereas, the denominator included
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all those patients meeting the inclusion/exclusion criterions and flagged as “1” or “0” both. In
order to meet this research objective, McNemar’s Exact Test was performed separately for each
of the drug categories.
A McNemar’s Exact Test was conducted rather than the original McNemar’s Test to
account for the small sample size employed in the study. This was also done keeping in mind
that, the sum of discordant pairs in all the drug categories were less than 25 i.e. b+c< 25. A 2x2
contingency table was obtained as a result of this analysis and odds ratios with confidence
intervals ranging from 5% to 95% were also obtained. Odds ratio results signified the odds of
adherence (depending upon the drug class) in post-period as compared with pre-period.
McNemar’s Exact Test results are described below by drug category.
Diabetes: The required sample size for this analysis was 109 patients whereas the current
study had only 56 patients, therefore, sample size requirements were not met. The results of 2x2
contingency table after performing the McNemar’s Exact Test (Table 4) suggests that there were
51 (91.07%) adherent patients in pre-period whereas there were 56 (100%) adherent patients
post-period. The test performed also yielded an exact p-value equal to 0.0625, greater than alpha
0.05. Using the results, the null hypothesis is not rejected. Therefore it can be concluded that
although there was an increase in the proportion of adherent patients from pre-period to postperiod, the difference in the proportion was not statistically significant.
The odds ratio of being adherent in post period as compared to pre-period was equal to
infinity. This can be attributed to the fact that no one who was adherent in the pre-period stayed
non-adherent in the post-period and no one who was adherent in pre-period became non-adherent
in the post-period. In this situation one of the discordant pairs was zero, leading to an odds ratio
equal to infinity. The odds ratio of infinity has a 95% CI ranging from 0.05 to infinity because in
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a case when OR equal to infinity, the upper exact confidence limit is set to infinity and the lower
limit is set to alpha, which is 0.05 for the current study. Therefore it can be concluded that there
was large difference between the proportions of adherent patients in post-period as compared
pre-period, however the difference was not statistically significant. Results of McNemar’s Exact
Test for diabetes drug category is shown in Tables 8 and 11.

Table 8: 2x2 Contingency Table for Diabetes
Post-Period
Pre-Period

Non-Adherent (%)

Adherent (%)

Non-Adherent 0

5 (8.93)

Adherent 0

51 (91.07)

Hypertension: The required sample size for this analysis was 95 patients whereas the
current study had only 89 patients, therefore sample size requirements were not met. A total of
80 (89.89%) patients were adherent in the pre-period as compared to 88 (98.88%) patients in the
post-period. The test performed yielded an exact p-value of 0.0215, less than alpha 0.05. Using
these results, the null hypothesis is rejected and it is concluded that the difference in the
proportion of adherent patients in pre-period and post-period is statistically significant.
When evaluating the odds of adherence, patients in the post-period had a 9 times higher
odds of adherence as compared to pre-period. Results of the McNemar’s Exact Test for the
hypertension drug category is shown in Tables 9 and 11.
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Table 9: 2x2 Contingency Table for Hypertension
Post-Period
Pre-Period

Non-Adherent (%)

Adherent (%)

Non-Adherent 0

9 (10.11)

Adherent 1 (1.12)

79 (88.76)

Cholesterol: A total of 70 (90.91%) patients were adherent in the pre-period as compared
to 76 (98.70%) patients in the post-period. The test performed yielded an exact p-value equal to
0.0703 greater than alpha 0.05. Using the results, the null hypothesis is not rejected. Therefore it
is concluded that although there was an increase in the proportion of adherent patients from preperiod to post-period, the difference in the proportion was not statistically significant.
When evaluating odds of adherence, patients in the post-period had a 7 times higher odds
of adherence compared to the pre-period. Results of the McNemar’s Exact Test for the
cholesterol drug category is shown in Tables 10 and 11.

Table 10: 2x2 Contingency Table for Cholesterol
Post-Period
Pre-Period

Non-Adherent (%)

Adherent (%)

Non-Adherent 0

7 (9.09)

Adherent 1 (1.30)

69 (89.61)
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In the pre-period, approximately 89.89% to 91.07% patients were considered adherent
depending upon the drug category. Whereas, the proportion of adherent patients ranged from
98.70% to 100% in the post period depending upon the drug category. Table 8 contains all the
results derived from the McNemar’s Exact Test for all the three drug categories.
Table 11. Results of McNemar’s Exact Test
Adherent Patients
(%)
Drug Class

Diabetes

Hypertension

Cholesterol

Pre-

Post-

Period

Period

51

56

(91.07)

(100)

80

Odds Ratio (CI)

Change in

DF

Proportion

P
(Two-Tailed)

0.05-Infinity

8.93

1

0.0625

88

9

8.99

1

0.0215*

(89.89)

(98.88)

(1.14-71.04)

70

76

7

7.79

1

0.0703

(90.91)

(98.70)

(0.86-56.89)

*Significant at α = 0.05
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DISCUSSION
This study aimed to explain the impact of medication synchronization (med sync) on
medication adherence. Adherence plays a crucial role in the Centers for Medicare and Medicaid
Services’ (CMS) Star Rating System which is designed to assist Medicare beneficiaries in plan
selection. Among the five measures used by CMS and Pharmacy Quality Alliance (PQA) for
calculating the Star Rating, three of them are related to the medication adherence.3,7 From a
clinical perspective, adherence is vital to attain the therapeutic effect of medication therapy, so it
is critical to understand the importance of med sync program in improving the medication
adherence of patients.
A quasi-experimental pre-post study design was employed for this study using pharmacy
prescription fill data from various independent community pharmacies located in different
regions of Mississippi. Patients were compared on the main outcome measure, medication
adherence, before and after the medication synchronization intervention. Because this study
employed a pre-post study design, patients served as their own control. Drug classes in the CMS
Five-Star Quality Rating System that were examined include oral diabetes medications,
hypertension medications and cholesterol medications. Data was utilized from three different
pharmacies located in different regions of Mississippi.
Discussion of findings
The only demographic information available for patients in this study was age. Most
patients were between 60 and 80 years old. Similar age trends were noted in an evaluation of
another med sync program conducted by Holdford et al.1 This is in line with the expectation that
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older patients utilize more prescription medications than younger patients, and therefore are
potentially better candidates for a med sync program.27
Because average PDC values in the post-period were higher than average PDC values in
the pre-period, it is evident that the medication adherence improved after being enrolled in the
med sync program. After performing Wilcoxon Signed-Rank Tests, it was found that the
improved adherence was statistically significant in all three drug categories. It is worth noting
here, however, that pre-period adherence values were exceptionally higher than the investigators
expected. For example, average pre-period PDCs for all drug categories was 0.94, increasing to
0.99 after med sync was implemented. It is possible that patients who were most adherent, and
thus being more present in the pharmacy for their refills and engaged in their own care, were not
only perceived as needing med sync more, but also easier to recruit into the program, thus
resulting in self-selection bias into the med sync program. Meaning that, patients in this study
may not have been representative of typical patients in each of these pharmacies.
After finding that the PDC values between the pre-period and post-period significantly
improved, a follow up analysis was conducted to confirm these findings. For this purpose, the
proportion of adherent (PDC ≥ 0.80) patients in the pre-period and post-period was calculated.
Upon the formulation of a 2x2 contingency table the McNemar’s Exact Test for small sample
sizes (where the sum of discordant pairs were less than 25) was performed. For oral diabetes
medications, an increase of approximately 8.93% adherent patients from pre-period to postperiod was noticed. However, this increase in the proportion of adherent patients was not
statistically significant.
Lack of a statistically significant change could be attributed to the small sample size for
this drug category and presence of too much ‘noise’ in the data. The small sample for this study
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can be explained by the fact that our sample largely consisted of adults between 60 and 80 years
of age. In fact, four out of 56 in the diabetes medication category were between 80 and 100 years
old. It is likely that older diabetes patients are being treated with insulin after first-line oral
diabetic treatments used in the earlier stages of their disease. From a clinically practical
standpoint, however, it is impressive to note that 91% of patients were considered adherent prior
to the intervention, while 100% were considered adherence after the intervention. So while not a
statistically significant change, adherence in more than 100% of patients cannot be obtained.
Again, the fact that 91% of patients were adherent prior to the intervention may be reflective of a
biased sample.
In the hypertension category, there were 80 (89.89%) adherent patients in the pre-period
whereas there were 88 (98.88%) adherent patients post-period. As consistent with the direction
of the previously stated hypothesis, an increase of approximately 8.99% adherent patients from
pre-period to post-period was noticed. Despite a small sample and underpowered test,
statistically significant improvements were still detected.
As with diabetes medications, the increase in the proportion of patients adherent to
cholesterol medications was not statistically significant. Looking again from a clinical
perspective, nearly 91% of patients were considered adherent prior to the intervention, while
nearly 99% were considered adherence after the intervention. So again, while not a statistically
significant change, practically speaking, having nearly 99% of patients adherent to their
cholesterol medications is would be all accounts be considered reasonable in the practice setting.
Limitations
The study contains several limitations. The findings of current study may not be
generalizable to a national population considering that this data was acquired from community
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pharmacies located in Mississippi. The literature suggests that pharmacists can influence
medication adherence, and each pharmacy will likely have its own impact on medication
adherence, which was not controlled in this study.1 The study also did not control for risk factors
impacting adherence such as general comorbidities of patients, individual risk factors associated
with respective drug categories, health insurance status, race, gender, severity of disease
conditions, patients’ motivation to be enrolled in med sync. Also, the findings from the current
study will merely reflect the association between adherence and med sync and does not imply
causality.
We were unable to identify exact index dates for each patients due to documentation
issues in the pharmacies. Therefore, an estimate of the index dates was taken using available
information such as enrollment dates and monthly prescription dispense dates. An algorithm for
index date selection was used, such that the index date was the date after the enrollment date
upon which the patient received multiple monthly prescriptions on the same date for at least
three months.
Sample size requirements were not met for the diabetes and hypertension drug categories
for McNemar’s Exact Tests and sample size requirements were not met for diabetes and
cholesterol drug categories for the Wilcoxon Signed-Rank Tests, making these tests
underpowered. Upon discussion with the pharmacists, it was found that the med sync program
offered in the pharmacies was an opt-in program in which the patients must consent to be
enrolled in the program once the offer to join the program is made by the pharmacist. This can
lead to self-selection bias because patients in the med sync program might be more engaged in
their own health relative to other patients who chose not to enroll in the program. Not
surprisingly, upon conversations with pharmacists, it was found that patients visiting the
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pharmacy multiple times a month for refills were considered the best candidate for med sync.
Although recruiting these patients is consistent with the objectives of med sync, simultaneously,
it also creates a pharmacy-selected pool of patients who are highly enthusiastic about
maintaining their health leading to a possible bias in the study.
Another challenge in this study was that, each of the pharmacies had different types of
pharmacy management software which can lead to discrepancies in the data overall. Also, using
PDC as an adherence measure assumes that if medication is possessed, it is consumed as well. In
reality, this might not be the case. Additionally, patients who were excluded from the study due
to a 90 day or more gap between fills might have not actually been non-persistent, but instead
might have switched pharmacies or been advised by the prescriber to discontinue taking their
medication. Considering the nature of the study as well as the nature of the pharmacy
prescription transaction data used, it was outside the scope of this study to address these latter
limitations.
Directions for future research
This study evaluated how med sync can potentially improve medication adherence of
patients by employing a quasi-experimental pre-post study design by utilizing pharmacy
prescription transaction data collected from independent communities situated in various regions
of Mississippi. Moving forward, studies evaluating similar objectives should employ a
randomized case control design. This will help to control for the self-selection bias that can occur
when patients are approached about enrollment in med sync. Self-selection bias can lead to the
enrollment of those patients who were motivated to improve their adherence already and can
result in inflated PDC results both before and after a med sync intervention.
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Also, considering the nature of prescription transaction data and the unavailability of the
important risk factors that need to be controlled, a survey research could be used to supplement
the secondary data evaluation of med sync on medication adherence. This may help researchers
extract valuable information from the patients which is otherwise difficult to obtain from a
pharmacy dispensing database.
Researchers conducting similar studies in the future should ensure consistent, controlled,
and structured med sync programs. In particular there should be adequate and accurate
documentation. Ideally, a dedicated researcher proficient with the process of medication
synchronization should be appointed in the pharmacy to manage the program. Creating a
comprehensive documents containing the guidelines to conduct med sync program should be
created and should be followed strictly while implementing the program. Most importantly,
future researchers should assure that med sync programs are adjusting refills based on patientreported adherence, not just refilling a month’s worth medication, assuming that they patient has
been perfectly adherent. Doing the latter results in inflated adherence rating, and may be
considered fraud by stakeholders reimbursing pharmacists for good adherence rates.
The convenience that comes with med sync for pharmacy patients is a relatively
unexplored area. Not only are patients profoundly reducing the number of visits they make to the
pharmacy, but their medication is already available in the pharmacy when they visit. Most
importantly, med sync should allow for increased pharmacist contact and attention due to
streamlined workflow. In theory, it can be assumed that all of this would lead to patient
satisfaction. Future studies should aim at exploring such non-clinical benefits, or even healthrelated quality of life as a result of the med sync. These kind of assessments are of utmost
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importance for third parties who may be paying pharmacists for such interventions and to
maintain emphasis on a patient centric model.
Better inventory management, streamlined work flow, and less walk-in traffic are some
of the benefits that a pharmacy receives when practicing med sync program. Considering that the
pharmacist has a critical role to play in the program, the attitudes and satisfaction level of the
pharmacist derived from a med sync program should also be assessed in future studies.
With scheduled monthly visits by the patients purchasing multiple prescription
medications for the month, there is an expected increase in the revenue for the pharmacy. At the
same time, there in a decrease in the overall walk-in visits which might would lead to a decrease
in the upfront sales. A study in the future, evaluating the net benefit of this program might would
help the pharmacy to understand med sync benefits from a monetary perspective.
Upon discussion with the pharmacist, it was found that pharmacies adjust the upcoming
prescription’s days of supply if a patient has not been adherent in the previous month or have
missed few doses. Although they pay the same amount of co-pay associated with the drug they
sometimes receive lesser quantity of doses depending upon their consumption in the last month.
Some patients were not in favor of this and left the program because they did not wish to pay the
same amount of co-pay and receive lesser drug quantity. From this we can infer that co-pay or
co-insurance has an important role to play in the med sync program, therefore future studies
should aim at exploring this issue in detail.
In exploring the core issue of the current study, improving adherence is most salient to
stakeholders of med sync, particularly payers. There is a wealth of literature demonstrating
positive intermediate and other clinical outcomes as a function of medication adherence. Linking
improved adherence as a result of med sync with health outcomes should be a priority of future
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med sync research, and will inevitably become a necessity for payers considering reimbursing
pharmacies for such services. In addition to linking med sync to health-related outcomes,
research should attempt to link med sync with health costs related to emergency room visits or
hospitalizations. A detailed cost analysis could be performed by linking synchronized patients to
Medicaid and other claims databases.
Conclusion
This is the first study to assess the impact of medication synchronization on medication
adherence while employing a quasi-experimental pre-post study design by utilizing the pharmacy
prescription transaction data from various independent community pharmacies in Mississippi.
The results indicated that after being enrolled in med sync, medication adherence generally
improves. When linked to literature that correlates adherence with positive health and economic
outcomes, med sync programs can offer potential benefit to the healthcare system.
An important stakeholder in med sync is Centers of Medicare and Medicaid Services’
(CMS) because they evaluate Medicare Part D plans on the basis of Star Rating system which is
useful in making quality based payments to Medicare Advantage Plans (MA-PDs), selling
benefits of prescription drug plans (PDPs) and assisting Medicare beneficiaries in plan selection.
Results of this study and similar ones conducted in future will become even more important with
the boom of commercial Part D plans making it necessary to monitor the adherence and
subsequent health outcomes.
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